ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1977

Transcriptional Perturbation of RA-Risk Enhancer By CRISPR-DEADCAS9 Regulates LONG Range GENE Targets

Kate Duffus1, Maria Imran2, Gisela Orozco3, Helen Ray-Jones2, Antony Adamson2 and Stephen Eyre4, 1Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, 2University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK, Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, 4NIHR Manchester Musculoskeletal Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: genetics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Genetics, Genomics and Proteomics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Findings from genome wide association studies in complex diseases indicate over 90% of genetic variants associated with risk of developing disease are found outside protein coding regions, suggesting regulation of gene expression is key to disease susceptibility. For rheumatoid arthritis (RA) it has been demonstrated that risk variants are found in gene regulation regions, and are significantly enriched in T-cell specific enhancers. In addition, a significant proportion of associated variants lay some distance from the nearest gene and enhancers may not necessary regulate the closest gene, effectively ‘skipping’ genes. Using chromatin conformation technology (HiC) we have demonstrated that an enhancer region intronic of the COG6 gene, containing variants associated with RA, make robust physical contact with the promoter of FOXO1, almost 1Mb away on the linear chromosome. COG6 is not an obvious candidate risk gene for RA, whilst FOXO1 is involved in T-cell development and shown to be over expressed in RA synovium. The challenge now is to provide empirical evidence that the enhancer found within COG6 does regulate FOXO1 expression, and how an RA risk genetic background affects this regulation

Use CRISPR-Cas9, to perturb the COG6 intronic enhancer region and measure the downstream effect on the expression of FOXO1.

Methods:

We utilised a modified form of the Cas9 enzyme, dead Cas9 (dCas9), that can precisely target DNA, but will not induce a cut. Using the dCas9 attached to either enhancers (p300) or repressors (KRAB) of expression we investigated how perturbation of the enhancer intronic of COG6 changed the expression of FOXO1.

We designed 3 guides across the COG6 enhancer, and transduced a cell line (HEK293) using a lentiviral dCas9 CRISPR system, with either dCas9-KRAB or dCas9-p300 and each of the three guides. We cultured the cells until 70-80% confluent, GFP sorted the cells and then extracted RNA. A quantitative PCR was performed (QuantStudio) for both COG6 and FOXO1 gene transcript expression and normalised to housekeeping genes.

Results: Up to 90% of HEK cells were tranduced with the dCas9 enzyme and guide, and these were sorted by FACS using GFP to sort the top 60% . The 3 guides gave consistently increased levels of FOXO1 expression with the dCas9-p300, compared to both control and dCas9-KRAB (p=0.02). This was particular evident for guide 3, with a 40% increase (p300) and 10% decrease (KRAB) of FOXO1 expression observed. Expression of COG6 was also perturbed, but in a less consistent manner, with both increase and decrease expression for KRAB and p300

Conclusion:

Over 90% of HEK cells were tranduced with the dCas9 enzyme and guide, and these were sorted by FACS using GFP to sort the top 60% . The 3 guides gave consistently increased levels of FOXO1 expression with the dCas9-p300, compared to both control and dCas9-KRAB (p=0.02). This was particular evident for guide 3, with a 40% increase (p300) and 10% decrease (KRAB) of FOXO1 expression observed. Expression of COG6 was also perturbed, but in a less consistent manner, with both increase and decrease expression for KRAB and p300.


Disclosure: K. Duffus, None; M. Imran, None; G. Orozco, None; H. Ray-Jones, None; A. Adamson, None; S. Eyre, None.

To cite this abstract in AMA style:

Duffus K, Imran M, Orozco G, Ray-Jones H, Adamson A, Eyre S. Transcriptional Perturbation of RA-Risk Enhancer By CRISPR-DEADCAS9 Regulates LONG Range GENE Targets [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/transcriptional-perturbation-of-ra-risk-enhancer-by-crispr-deadcas9-regulates-long-range-gene-targets/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/transcriptional-perturbation-of-ra-risk-enhancer-by-crispr-deadcas9-regulates-long-range-gene-targets/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology